Press Releases

March 29, 2023

Lucy Therapeutics, Inc. announced the appointment of Christopher J. Winrow, Ph.D., a neuroscience and translational medicine expert, as Chief Scientific Officer.

Visit Link

October 13, 2022

Lucy Therapeutics Debuts Novel Therapeutic Agents for Parkinson’s Disease at Michael J. Fox Foundation Annual Conference

Visit Link

April 11, 2022

Lucy Therapeutics Receives $4.9 Million Grant from Michael J. Fox Foundation

Visit Link

In the News

March 8, 2023


How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.

Visit Link

January 3, 2023

Cultivating Greatness

Amy Ripka, Founder/CEO of Lucy Therapeutics, shares her amazing story of driving disruptive innovation in the biotech industry. She describes her scientific "curiosity" that led to the formulation of her disruptive idea, and the gutsy "courage" that drove her to found Lucy Therapeutics against all odds, overcoming the industry's significant resistance.

Visit Link

December 14, 2022


Lucy: mitochondrial solutions to CNS diseases. Lucy Therapeutics views mitochondrial dysfunction as a common and core driver of many CNS diseases, and aims to build a pipeline of programs against “rate-limiting” targets that gate the progression of that dysfunction.

Visit Link

December 7, 2022

Longevity Technology

Do mitochondria hold the key to a Parkinson’s breakthrough? Lucy Therapeutics founder on mitochondria, Parkinson’s and the importance of hypothesis-driven research and development.

Visit Link

November 19, 2022

Cultivating Greatness

Podcast: A creative conversation with Amy Ripka, Founder/CEO of Lucy Therapeutics and professional violinist, about how she leverages the principles of performing music to her own leadership practice.

Visit Link

September 12, 2022

Clinical Leader

Beyond Nuclear Genetics: Let's Think Differently About CNS Disease Targets.

Visit Link

June 27, 2022

Lab Central

Pride Q+A with Amy Ripka, CEO and Founder at Lucy Therapeutics

Visit Link

February 11, 2021

ACS Boss Talk

Amy Ripka has over 30 issued patents and has been involved in multiple INDs in different therapeutic areas. She has deep connections in the medicinal chemistry community with long-time service to the ACS MEDI Executive Committee and was the elected Chair of the 2012 Medicinal Chemistry Gordon Research Conference.

Visit Link

September 16, 2020

University of Wisconsin-Madison News

A Rich History of Research and Mentorship

Visit Link

March 8, 2020

Chemical & Engineering News

Amy Ripka on being a CEO: ‘Nobody ever got anywhere by listening to No’

Visit Link